Renaissance Capital logo

KRRO News

US IPO Weekly Recap: Oncology biotech Aprea Therapeutics finishes on top in 4-IPO week

ADCT

Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price IPOs this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or...read more

Frequency Therapeutics prices downsized IPO at $14, the low end of the range

Korro Bio (Frequency Therapeutics) logo

Frequency Therapeutics, which is developing a regenerative therapy for hearing loss, raised $84 million in a downsized IPO by offering 6 million shares at $14, the low end of the range of $14 to $16. The company originally planned to offer 6.7 million...read more

5 biotech IPOs are pricing tonight with 2 more on the calendar

Korro Bio (Frequency Therapeutics) logo

After a wave of biotech launches last week, one more filed terms this week. Seven biotechs are currently on the Renaissance IPO calendar, four of which are targeting billion-dollar valuations. Five are set to price tonight. Swiss biotech ...read more

US IPO Week Ahead: A wave of biotechs and billion-dollar valuations in 6-IPO week

ADCT

Six IPOs plan to raise $596 million in the week ahead, with two biotechs targeting billion-dollar-plus valuations. Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million at a $1.8 billion valuation. Insiders have indicated on...read more